We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Track real-time Director Deals activity on the London Stock Exchange (LSE)
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.50 | 248,021 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 7.00 | 8.00 | 7.50 | 7.50 | 7.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Business Services, Nec | 2.86M | -14.23M | -0.0441 | -1.70 | 24.2M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:10:18 | O | 10,546 | 7.647 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 17/6/2025 | 07:00 | UK RNS | Angle PLC EACR 2025: Innovation in AR expression profiling |
| 17/6/2025 | 07:00 | UK RNS | Angle PLC EACR 2025: Data demonstrating DNA dual analysis |
| 10/6/2025 | 07:00 | UK RNS | Angle PLC Novel discoveries into the biology of cancer |
| 09/6/2025 | 07:00 | UK RNS | Angle PLC POSTING OF ANNUAL REPORT AND NOTICE OF AGM |
| 06/6/2025 | 07:00 | UK RNS | Angle PLC Board Changes |
| 28/5/2025 | 13:31 | ALNC |  Angle shares fall on weak 2025 outlook despite narrower annual loss |
| 28/5/2025 | 11:06 | ALNC | AIM WINNERS & LOSERS: Frontier Developments revenue to beat consensus |
| 28/5/2025 | 07:00 | UK RNS | Angle PLC Preliminary Results |
| 23/5/2025 | 07:00 | UK RNS | Angle PLC Notice of Results |
| 28/4/2025 | 07:00 | UK RNS | Angle PLC RESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME |
Angle (AGL) Share Charts1 Year Angle Chart |
|
1 Month Angle Chart |
Intraday Angle Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 19/6/2025 | 15:38 | ANGLE PLC - 2019 THREAD - LIQUID BIOPSY COMPANY | 29,502 |
| 15/4/2025 | 15:05 | SHAREHOLDERS ACTION GROUP | 585 |
| 26/3/2025 | 23:48 | AGL has been Jinxed by the God of Shite. 10p Target | 285 |
| 18/2/2025 | 11:56 | ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET | 11,464 |
| 12/2/2025 | 20:41 | 6 monthly AGL check in | 4 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 14:10:19 | 7.65 | 10,546 | 806.45 | O |
| 12:33:01 | 7.65 | 100 | 7.65 | O |
| 11:22:04 | 7.33 | 5,450 | 399.25 | O |
| 11:12:08 | 7.33 | 25,000 | 1,831.25 | O |
| 08:40:23 | 7.62 | 50,000 | 3,811.00 | O |
| Top Posts |
|---|
Posted at 05/6/2025 18:26 by 5oletrader Bones - NOW you're telling me what the truth is? So were you NOT being truthful before? Here's a truth - YOU deflected from almost every point I raised. You're NOW attacking AN (who I never mentioned) while subtly going after ME and OTHERS who've spent TIME trying to break things down.I've said it BEFORE - I post evidence. Ideas. With sources. With links. BECAUSE I want challenge. I want INFORMED pushback. That's HOW I learn and refine my OWN view of AGL. Unfortunately (and here we might agree) the quality of debate on this board had declined. You've made your feelings on AN clear - and that's fine. BUT this isn't JUST about him. You're IGNORING the broader context - the platform IP, the QUALITY of the data, the COMMERCIAL interest from credible players. You THROW comments out like "blind belief" and "small links." So let's breakdown those: - AZN funded and developed assays with AGL - tell me WHY they are doing that? - EISAI paid for a study, AGL delivered, now more discussions - tell me WHY they are doing that? - ILLUMINA has started co-marketing - tell me WHY they are doing that? - BIOVIEW paid £1.2M for 3rd-party rights with commercial intent - tell me WHY they are doing that? - RECURSION fully funded ongoing collaborative study - tell me WHY they are doing that? - BLISSBIO is exploring progression of BB-1701 - tell me WHY they are doing that? - AGL is confirmed to be engaged with OTHER major pharma - tell me WHY they are doing that? - Discussions are ongoing with TOP-TIER diagnostic MEDTECH companies - tell me WHY they are doing that? - NHS England is in active dialogue - tell me WHY they are doing that? - SOLARIS remains live via DOMINO - tell me WHY they are doing that? - EMBER2 is enhancing the same RNA workflows as DOMINO - tell me WHY they are doing that? - INFORM study involves six NHS Trusts - tell me WHY they are doing that? And YOU call all that "tenuous"? You don't address the substance because it doesn't fit the picture you're trying to paint! And don't shift this BACK to me. What I've posted is backed by company disclosures, real-world news, and sector related info. That's SHARING research. It's NOT about being right - it's about asking BETTER questions. That should be everyone's job here right? YES - the share price is near all-time lows. BUT price alone doesn't define value. And NO - I've NEVER claimed certainty. We CAN agree - low CASH is a real issue. But suggesting the company is waiting for a "rabbit out the hat" IGNORES what's already landed. Partnerships. Pharma-led funding. Platform progression. SLOWER than anyone wanted - yes - but VERY real. You call it "failure" because a mega deal hasn't dropped YET. That's a TIMELINE problem - NOT a platform problem. Clinical adoption is hard. We've always known that! You say you've followed AGL since the beginning. Fine. BUT being early isn't the SAME as being right. Yes, mistakes have been made. But to pretend nothing has changed in 18 months is just inaccurate. Things are advancing - AZN, ILLUMINA, RECURSION, EISAI, BLISSBIO etc - all happened. You just pretend they didn't! And NOW it sounds like you're calling in backup from SK - "even SK has turned." Maybe he has, maybe he hasn't. He can speak for himself. Timing is crucial - agreed. BUT calling it a "miracle comeback" misses what's really happening. NOBODY is saying it's de-risked. But this is the INFLECTION point - where retail SELLS out at lows, and institutions start MOVING in. AGL's near-term challenge is funding - NOT failure. And they've already listed multiple funding PATHWAYS - revenue, milestones, licensing, partner income, debt, and equity. The QUESTION isn't IF they raise - it's HOW, WHEN, and on WHAT terms? What lands NEXT is ALL that matters now. |
Posted at 04/6/2025 20:34 by 5oletrader Bones - I'll be honest mate. You've been around a long time, but I've started taking you LESS seriously. Your posts seem to REFLECT your position - pessimistic when you've SOLD out, optimistic when you've BOUGHT in.So is it really AGL you're frustrated with - or that you SOLD at these low levels and can't bring yourself to BUY them back or buy back in higher? Feels like the play now is to TALK it down - again? And let's not forget - just YESTERDAY you said you'd moved on! You were pumping HVO. - “for me it was simple to switch to HVO. 40-60m revenue, cash generative, 40m in the bank. Granted the market and margins aren't what AGL could achieve - but AGL is just a could, and very little evidence to the contrary. Will be 50 years before AGL hits those revenues - if it survives that long. I've heard enough BS from AN to be glad to move on." Fair enough. But if you've REALLY moved on - WHY are you back here TODAY? It's obvious - financially you're OUT and emotionally you're IN? You can't move on! Let's be CLEAR about a few things you're NOW claiming: “Need to compliment AGL's bank balance though and thus far little evidence of that" Really? - EISAI paid 250k - and they're discussing more - AZN paid 150k and 670k for assay development - now we're waiting on them - RECURSION - fully funded agreement. - BIOVIEW - 1.2M for HER2 assay, with third-party inclusion allowed. That's NOT "no evidence” That's financial COMMITMENT across the board. No? The real question is - what comes NEXT? - “God it takes too long" Compared to what? How long does it take to develop diagnostics and get clinical adoption? That's NOT a delay - it's the REALITY of medtech. The better question - how FAR along are AGL? - “if the benefits are so obvious, why hasn't anyone signed up or bought AGL?" No one knows if or when a buyout happens - but it's NOT OVER. And how do you know it won't? - “other techs are making progress and seeking the spoils" Partially agree - but are others now paving the way for AGL? You're assuming "progress" means revenue right now. How far away is "when"? - “Hampered by lack of scale and overlooked" By who, exactly? Because: - AZN is funding work. - ILLUMINA is co-marketing. - NHS is talking. - RECURSION, BIOVIEW, EISAI, BLISSBIO are involved. So - who's overlooking them? - “until a big player signs up properly, it's on the sidelines" Isn't joint development, funding, co-marketing a sign of intent? Who sidelined AGL - and where's the evidence? - “it could happen, but hasn't so far. How much longer?" You sound like someone who KNOWS it's coming, BUT got burned being EARLY. My question is - will your frustration cause you to be too LATE? |
Posted at 04/6/2025 12:40 by 5oletrader Htrocka - curious why'd you drop that link? Because AZN used ctDNA in SERENA-6? Are you implying AGL's irrelevant now? Trying to debunk the "gold standard" reference? Instead of casting doubt, why not look at what "actually" just HAPPENED?Liquid biopsy for treatment DECISIONS has just been given the green light! AZN used GH's ctDNA test to detect ESR1 mutations before anything showed on scans - a signal that the cancer's adapting and endocrine therapy is LOSING effect. When GH flagged it, AZN switched patients early to camizestrant, their next-gen SERD. Result - 56% lower risk of progression. That's massive.LIQUID BIOPSY ENABLED that DECISION. So yes - ctDNA has now proven it can triage. Catch trouble early. Support early drug switching. Not arguing that. But ctDNA can't tell you what the tumor is doing NOW. NOT how it's changing. NOT which targets are still expressed. NOT what phenotype is emerging. They're reading fragments in blood - NO shape, NO function, NO protein expression. Step in - PARSORTIX isolates live, intact CTCs. AGL has developed a HER2 assay that actually works on those cells. Why does that matter? Because HER2 isn't binary anymore. It's a spectrum - high, low, ultra-low - and it FLUCTUATES over time. AZN "is" developing DRUGS across that spectrum. So if HER2 expression changes - AND IT DOES - you need to track it in real-time. Biopsy can't. ctDNA can't. AGL can. With PARSORTIX they can now: - MEASURE HER2 expression in real-time - including "low" and "ultra-low" - TRACK HER2 shifts as the disease evolves - DETECT mismatches between past biopsy and current tumor behavior - STRATIFY patients for HER2-targeted drugs with more precision ctDNA can't do any of that! NOT NOW! Maybe NOT EVER! How could the actual workflow look? - GH screens: flags ESR1 or other mutations early - AGL steps in: profiles HER2, tracks expression, checks phenotype shifts - AZN refines trial cohorts, improves inclusion criteria, boosts chance of success Ponder that! This isn't GH vs AGL. It's: Step 1: DETECT a problem (GH) Step 2: UNDERSTAND the biology and act smartly (AGL) Sequential. Not competitive. You NEED both! If anything, this study strengthens AGL's case. SERENA-6 "PROVED" liquid biopsy CAN drive early intervention. Now the focus moves to deeper stratification. That's where CTCs - and PARSORTIX - do what ctDNA can't! So maybe you should stop trying to spin it. Why do you think AGL and ILLUMINA are "both" saying CTCs complement ctDNA??? Because they DO!!! |
Posted at 03/6/2025 21:02 by 5oletrader fhmktg - I'm happy to be real. Things haven't moved as fast as anyone hoped. SOLARIS was announced in 2022. It's now mid-2025 and there's no test, no revenue. The U.S. lab is closed. That's the reality - and no one's pretending otherwise.But are you implying SOLARIS is now at some DEAD end? If so, I disagree. SOLARIS aren't walking away from AGL - they are in fact going DEEPER. They've got over 400 patient samples banked from the DOMINO study with MidLantic, Solaris's clinical arm. And instead of rushing out a half-baked test based on cell counts or imaging, they've CHANGED strategy. WHY? Because just finding tumour cells isn't enough. Now they're using RNA sequencing to go after the molecular signals that DEFINE aggressive disease. It's the SMARTER move! Anyone who understands PROSTATE cancer knows the problem isn't just detecting it - it's knowing which cancers matter. Most PROSTATE cancers are low risk. Treating them aggressively causes MORE HARM than good. What doctors actually need is a way to tell which cases to ACT on BEFORE doing a BIOPSY. I think AGL want to build - an RNA-driven assay that uses whole, live CTCs to PREDICT disease severity. If they pull it off, it's not just a screening tool - it becomes PART of the clinical DECISION process. - Do you BIOPSY? - Do you TREAT? - Do you WATCH and wait? That's the level they're aiming for! So, NO, this doesn't "go against" the large pharma strategy like you stated - It's right in the middle of it! The plan has always been to use PARSORTIX to build clinically validated, real-world assays from live CTCs - not just research kits. That's EXACTLY what pharma companies are looking for - tests that can inform TRIALS, TRACK response, and DETECT aggressive disease earlier. SOLARIS feeds directly into this. If AGL can prove they can build a robust, blood-based molecular test for aggressive PROSTATE cancer, it's proof of concept. It shows they CAN access and profile of live CTCs non-invasively - the thing pharma actually CARES about. Same logic applies in BREAST cancer - It's systematic - prove the tech (think HER2 and BIOVIEW assay) in real clinical settings, then fold it into pharma pipelines as part of the development workflow. That's the whole point. And - this isn't just theory. The BARTS pilot showed that PARSORTIX "can" reliably harvest CTCs. The SOLARIS study was built to go BEYOND that. Now they're layering on RNA - which gives a much more POWERFUL classifier. That's why it's taking time. Because it has to actually WORK! You also asked, "Why not just sell it to a U.S. company?" But sell what exactly? an unfinished test? There's a BIGGER play here. If AGL lands this test, SOLARIS becomes the route to market. 179 locations. 700,000 patients a year. The infrastructure is already in place - they're just waiting on a product that's ready. And don't forget ILLUMINA. AGL are "already" working with them. If this assay proves out, you've got a clear path - ILLUMINA sequencing, CLIA lab delivery, U.S. rollout. That's real SCALE - not a science project :) Yeah, it's been SLOW. I'm frustrated too. But a delay is NOTHING compared to building something that actually WORKS! It's still worth paying attention. |
Posted at 02/6/2025 22:21 by 5oletrader Thiopia - throw TEMPUS in the bin. Yeh they just added 1BILLION to their market cap of yet "another" ctDNA test. All they're doing is tracking tumour fragments. Bits of DNA floating in the blood.What if the REAL PLAY is studying whole, live tumour cells reacting to drugs in real time? If you're serious about AI in drug development, your focus shouldn't be on Tempus. It should be on RECURSION. RXRX. Everyone's talking about AZN and ILMN, but the curveball might already be in motion - and nobody's mentioned it. Back in NOV 2024, AGL quietly signed a fully funded pilot study with RECURSION. No noise. Just a one-liner saying - success may lead to further contracts supporting drug development projects with multiple large pharma companies. Plural. Plural. Plural. Most have ignored it. But this could be the trigger? RECURSION is an AI drug discovery powerhouse - backed by ROCHE, BAYER, SANOFI, MERCK. Their platform maps how REAL CELLS respond to drugs using high-resolution imaging and machine learning to find new candidates faster. Their bottleneck? BIOLOGY! Most labs still rely on immortalised cell lines - artificial, decades old, nothing like REAL patients. AGL changes that. PARSORTIX isolates live, intact circulating tumour cells from REAL PATIENTS in REAL TIME. Tumour evolution can be tracked live, over time. These are cells that can be studied, re-used, and tested against drug exposure dynamically. That's exactly what RECURSION needs! If CTCs prove viable on RECURSION's platform, this doesn't just open one door. It UNLOCKS multiple new drug development projects - not just with RECURSION, but with the BIG pharma partners already in play. AGL becomes their go-to biology provider feeding a pipeline that's already plugged in. That's NOT a one-off. That's infrastructure. That's SCALE. The deal was signed in NOV 2024. Most feasibility pilots run 6 to 9 months. We're right in the window. If it's moving forward, news could drop any time? So I'm NOT buzzing about TEMPUS, remember - Tempus reads fragments. However, RECURSION + AGL could be tracking live cell behaviour under drug pressure - in real time. That's not just a better diagnostic. That's BIOLOGY + AI at the SOURCE of DRUG CREATION. This could quietly be one of the most scalable, highest-value partnerships AGL could land. No? Sleep on this one at your own risk. |
Posted at 28/5/2025 14:58 by purchaseatthetop Yasx. It is a repeating scenario with nearly every drug or device UK company. AGL, STX, POLX etc etc. They all get FDA approval and the world is their oyster with soaring share price. Except that is the time to sell. The grind to get sales to cover overheads against diminishing belief is too much for all of them. On the way down it is slways the “must be a target at this price” story except it isn’t. Fortunately I got out of AGL at above 100p and then 70p. POLX I warned holders to sell on FDA approval (60p now 1.5p). I recently bought back into STX as finally they might be getting to cash positive when they will absolutely fly if it happens.But usually it is a licence to burn money! |
Posted at 26/5/2025 21:12 by bones698 Golden cross is the 50sma crossing the 200 sma I believe the others are just bullish crosses . People band the golden cross around to much these days without understanding what it actually is . That is a while off yet for agl if you look at the chart .The share price breaking the ,50 and 200 is bullish just not a golden cross Waterloo I think that's been covered they can raise below 10p if they announce a recap of the shares at the same time . Just because the ord value is 10p currently doesn't mean they can't raise below it ,it would be announced at the same time. Strange chart to read if you have a bit of experience . The lead upto last week was indicative of a possible placing coming sub 10p with the share price falling for several weeks ,the recent spike is either pis taking a gamble one isn't coming and angle are in talks so happy to continue on a going concern basis on the hopes such news will lift the share price significantly to allow a raise at a higher price at a later date . The other side is they are gambling one isn't coming but it does and got it wrong . Interesting few days ahead will find out which way it goes , I would say if there is no raise it's bullish provided they state they are nearing discussions concluding . Either way it's a gamble as is always with aim . Place tour bets |
Posted at 20/5/2025 15:25 by 5oletrader For anyone who wants to try a different lens - instead of repeatedly reading posts of the same old ilk.- Both the developed assays (AR and DDR) have been approved for use by AstraZeneca and we are currently using the assays to test blood samples from patients. These developments put ANGLE in the position to be able to execute large scale clinical trials for AstraZeneca. Supplier agreement to develop DDR assay - 150k - JOB DONE Supplier agreement to develop AR detection assay - 550k - JOB DONE So CURRENT STATUS: We are using the assays to test blood samples from patients." QUESTION? (not one person switched onto this): - If AZN is ALREADY using these assays on patient samples, do you think AGL are doing that for free? You could always 'ask' the company? - Maybe AZN are paying AGL on a per sample basis right now? NOT under a full clinical trial CONTRACT (yet), but under a real-world feasibility and operational validation phase. Why? Because the R&D is JOB DONE and now the focus shifts to pre-deployment QA. - AGL - is NOW on the BRIDGE: At pre-deployment QA phase - the final step between development success and LARGE-SCALE integration! - So while 'some' spread FUD about Parsortix being useless and AZN losing interest - ask yourself - is it? and are they? What we KNOW: - The assays (AR and DDR) are validated, in use, and described by AGL as "APPROVED FOR USE BY AZN". The story is now about operational readiness. How long? This QA phase typically spans 6-12 months in similar diagnostics rollouts. While AGL hasn't confirmed timelines (how far along this time frame are AGL?), a plausible to-do list include: - Testing hundreds of real patient samples under clinical trial-like conditions - Stress-testing logistics (turnaround, reproducibility, sample integrity across locations) - Aligning with ILMN's downstream workflows (multiomic compatibility, data handling, cost-per-sample) - Standardising SOPs across internal teams and external trial sites Also, - How many patient samples will AZN want to stress test? 100? - How many cancer TYPES will AZN want to run 100 samples on? Lung, Breast, Ovarian, Blood, Prostate, Liver, Pancreatic? 700 samples? Possible? What will AGL be charging on a per sample basis? 2k+? - The point = SHORT TERM REVENUE GENERATION. Hence the cash runway to 2026. This also ties in directly with AGL's latest trading update: - We expect revenues in 2025 to be higher than 2024, with the potential for a major Phase 3 clinical trial." Also Why mention Phase 3? Companies don't reference Phase 3 lightly in financial updates - to me it signals live dialogue with partners and internal planning aligned to real clinical deployment. You don't just say "potential for Phase 3"! That ONLY happens if pre-deployment QA is progressing well. - TRIPARTITE" - KNIGHTS of the ROUND TABLE: In my opinion this isn't three companies acting independently. It's a QUIETLY coordinated triad - AZN, ILMN, and AGL - shaping the future of oncology diagnostics on their terms. - AZN brings the drugs, the trials, and the regulatory clout. - ILMN brings the omics platforms, data engines, and healthcare penetration. - AGL brings the patient-side sampling tech that makes real-world blood-based stratification viable and scalable. I'd argue they are engineering the clinical diagnostics pipeline from front-end capture to treatment outcome - and because they control every layer of that stack, they also control what gets disclosed, when, and how! - No flashy press releases. No early declarations. Why? Because real competitive advantage comes from: - Building the pipeline quietly - Validating it internally - Locking in exclusivity and standards - And launching with scale and authority, not drip feeding headlines Are they focused on building a globally dominant diagnostic machine? - Is the narrative being held back on purpose? Because when it's finally revealed, it will already be fully integrated, clinically validated, and commercially aligned. - Its positioning 101! - AZN + ILMN - TELL ME WHAT YOU WANT, WHAT YOU REALLY REALLY WANT: Let's not overcomplicate this - both want FULL control of the cancer patient journey, from first blood draw to treatment decision, powered by real-time molecular data. And they're racing to scale it globally: - ASTRAZENECA: Their goal is precision patient stratification at scale - across trials and clinical settings. In clinical TRIALS, that means: - Enrolling only the right patients (AR, DDR, HER2 etc) - Faster recruitment, faster readouts, faster approvals - Biomarker-defined subgroups to maximize drug efficacy and hit endpoints In clinical PRACTICE, that means: - Ensuring the right patient gets the right drug - Real-time companion diagnostics to support drug prescriptions (e.g. EnHertu for HER2-low) - Avoiding resistance and failure by monitoring evolving biomarkers via repeat blood tests AZN want a standardised front end that plugs into global trial networks and oncology clinics. - ILLUMINA: Their goal is owning the data funnel - from blood tube to omics analysis. In clinical TRIALS, this means: - Every patient = multiomic dataset (DNA, RNA, epigenetics, proteomics) - Fed into Illumina systems for sequencing, AI analysis, and reporting - Positioned as the gold standard for pharma biomarker discovery In clinical PRACTICE, this means: - Plugged into national health systems and hospitals - Recurring revenue from sequencing, reagents, and downstream informatics - Monetising insights via partnerships, data licensing, and personalised medicine platforms ILMN want clean, structured input for their machines and software. - ANGLE: Angle solves the front-end problem for both AZN and ILMN: - Captures viable CTCs, not just cell-free debris - Enables dual analysis from the same blood draw - Standardised, IP-protected process with regulatory momentum - Scalable, automatable, and accredited lab compliant This is the infrastructure that makes the story possible. And; IF" AZN and ILMN want FULL control from bench to bedside - they either: - Buy ANGLE, or - Lock it in permanently with exclusive rights - The webinar is the first JOINT MARKETING initiative for ANGLE and ILLUMINA. Because it harvests intact cancer cells (rather than DNA fragments of dead cells), ANGLE's Parsortix system offers the potential to undertake multiomics by enabling RNA and protein sequencing on Illumina platforms which is "NOT POSSIBLE" with ctDNA. - Either way, this ends on ANGLE's terms - not the bulletin boards. - CASH FUD - QUESTION?: - If AZN is already using the tech, already paying for samples, and already planning Phase 3 - are we closer to dilution or collaboration??? Cash is NOT the current issue - it's a 2026 issue unless you ignore the facts already in play. ATB |
Posted at 11/4/2025 10:58 by ohwhatfun Reality on numbers for a raise.Share price 7.75p market cap £25m rough numbers 325m shares in issue. Those thinking can’t do than 10p. Nice 10p £10m raise for ease 100m shares. Which would mean 425m shares at a 10p price equates to the market cap jumping from £25m to £42.5m in an awful market in a constant failed promise company. It doesn’t work like that. Just to stay at a £25m market cap the raise for £10m would need to be around 4.5p. That’s the reality of dilution which is why share prices get trashed down pre raise then discounted. |
Posted at 09/4/2025 18:01 by ohwhatfun YasAs you probably well know, if a broker can’t drum up enough interest from their inner circle of clients, they have to seek others, which results in fire sale discount to get the money but also fund raise smoke visible well beyond any NDA barrier. In the worst case scenario the bucket shop game where all and sundry get to hear, followed by posts on sites saying raise coming, just after they go short. That forces the company to admit they are in the process of raising funds. The share price dives as punters exit, which serves those involved in the raise to push the strike price lower and lower, with often an agreed price then dropping further last minute (typical dirty trick). Share price falls and then discount from there, so it could he carnage here. Did Angle not say that last year it’s a tough market, some parties would not even entertain the NDA process to even look who was after funding. I was thinking 15p last time 8 ish p this time and a 12p average not really that bad, but you are right, a big fat rabbit out of the hat is needed and quick but even then a raise price could still be low. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
